Scienture's Arbli™ Drug Gains 12.5 Million New Covered Lives, Boosting Commercial Access
SCNX sits 62% above its 52-week low of $0.238.
Summary
Scienture Holdings announced expanded payor coverage and commercial access for its Arbli™ oral suspension, adding approximately 12.5 million covered lives nationwide. This is a critical positive development for the company, which recently disclosed substantial doubt about its ability to continue as a going concern and reported only $56.33K in Q1 revenue. Arbli™ targets the $219 million U.S. losartan market, and this increased access provides a concrete path to materially boost revenue. This follows a similar positive commercialization update for their REZENOPY™ product earlier this month, suggesting a focused effort on product market penetration.
At the time of this announcement, SCNX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.